(Q38639549)

5 September 2017

title

Is the NCI MATCH trial a match for gynecologic oncology? (English)

1 reference

5 September 2017

Kathleen N Moore

1

1 reference

5 September 2017

Robert S Mannel

series ordinal

2

1 reference

5 September 2017

language of work or name

English

0 references

publication date

13 November 2015

1 reference

5 September 2017

1 reference

5 September 2017

volume

140

1 reference

5 September 2017

issue

1

1 reference

5 September 2017

page(s)

161-166

1 reference

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

5 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.003

Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.003

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.003

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.003

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.003

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.003

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.003

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.003

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.003

Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done Yet

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.003

Improved overall survival in melanoma with combined dabrafenib and trametinib

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.003

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.003

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.003

A review of phase II trial designs for initial marker validation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.003

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.003

Adjuvant trastuzumab in HER2-positive breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.003

Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.003

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.003

Intratumor heterogeneity: evolution through space and time

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.003

The Brave New World of clinical cancer research: Adaptive biomarker-driven trials integrating clinical practice with clinical research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.003

NCI-MATCH trial pushes cancer umbrella trial paradigm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.003

Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.003

National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.003

Ovarian cancer: targeting the untargetable

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.003

Integrated genomic analyses of ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.003

Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.003

Integrated genomic characterization of endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.003

HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.003

HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.003

10.1016/J.YGYNO.2015.11.003

7 January 2021

Identifiers

DOI

1 reference

5 September 2017

1 reference